Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Adia Med Inc.
- Market Cap
- Unavailable
- Price
- $0.12
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.01%
- Volume
- 5.0K
About
Adia Med Inc. is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, while Adia Labs manufactures and distributes regenerative products. The company is also involved in multiple Institutional Review Board (IRB)-approved clinical studies.
Quick stats
Shares outstanding—
Computed float86.7M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001160420
AI Summary
AI-generated1/40
standardbullishearnings
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Adia Med reported Q2 revenue of approximately $485,000, representing 175% sequential growth from the first quarter, and recorded its first profitable quarter with net income of roughly $40,000.
First-half 2026 revenue reached $661,660, equating to nearly 95% of the company's total full-year 2025 revenue, indicating significant business acceleration.
The growth was driven by increased patient volume for regenerative treatments and expanded commercialization of Adia Labs biologics, alongside the launch of a Phase 2 clinical study for autism spectrum disorder.